Metavasi Capital LP lifted its position in PetMed Express, Inc. (NASDAQ:PETS - Free Report) by 48.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 340,302 shares of the company's stock after acquiring an additional 111,194 shares during the period. PetMed Express comprises approximately 0.6% of Metavasi Capital LP's holdings, making the stock its 25th largest position. Metavasi Capital LP owned approximately 1.65% of PetMed Express worth $1,640,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Arrowstreet Capital Limited Partnership lifted its position in shares of PetMed Express by 26.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 513,381 shares of the company's stock worth $2,474,000 after buying an additional 107,614 shares during the last quarter. Blair William & Co. IL boosted its stake in PetMed Express by 95.2% during the fourth quarter. Blair William & Co. IL now owns 20,300 shares of the company's stock worth $98,000 after buying an additional 9,900 shares in the last quarter. Geode Capital Management LLC lifted its stake in PetMed Express by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 224,788 shares of the company's stock worth $1,084,000 after purchasing an additional 3,558 shares during the period. American Century Companies Inc. lifted its holdings in shares of PetMed Express by 15.3% during the fourth quarter. American Century Companies Inc. now owns 33,662 shares of the company's stock valued at $162,000 after acquiring an additional 4,459 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of PetMed Express in the 4th quarter worth about $58,000. Institutional investors and hedge funds own 73.33% of the company's stock.
PetMed Express Trading Down 2.1 %
Shares of NASDAQ:PETS traded down $0.08 during trading on Tuesday, hitting $3.53. 49,093 shares of the company's stock traded hands, compared to its average volume of 287,677. The company has a 50-day moving average price of $3.70 and a 200-day moving average price of $4.45. PetMed Express, Inc. has a 52 week low of $2.90 and a 52 week high of $6.85. The company has a market cap of $72.81 million, a price-to-earnings ratio of 353.85 and a beta of 0.76.
PetMed Express (NASDAQ:PETS - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). PetMed Express had a net margin of 0.14% and a return on equity of 0.37%. On average, analysts predict that PetMed Express, Inc. will post 0.19 earnings per share for the current fiscal year.
Insider Buying and Selling
In other PetMed Express news, CEO Sandra Yvette Campos sold 60,463 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $3.31, for a total value of $200,132.53. Following the sale, the chief executive officer now owns 578,524 shares in the company, valued at approximately $1,914,914.44. The trade was a 9.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.10% of the company's stock.
Wall Street Analyst Weigh In
PETS has been the subject of several research reports. Morgan Stanley lowered their price objective on shares of PetMed Express from $3.50 to $3.20 and set an "underweight" rating for the company in a research report on Thursday, April 17th. StockNews.com cut PetMed Express from a "buy" rating to a "hold" rating in a report on Wednesday, April 23rd.
Check Out Our Latest Stock Report on PETS
PetMed Express Company Profile
(
Free Report)
PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Read More

Before you consider PetMed Express, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PetMed Express wasn't on the list.
While PetMed Express currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.